Chief of the Retina Service at Wills Eye Hospital discusses the impact of COVID-19 on retina research
Carl D. Regillo | | Opinion
The pandemic has had a significant impact on our work as all studies for newly recruited patients were put on hold. We also halted new recruitment to minimize the number of patients coming in, so as to limit their exposure to any risk, as well as the risk to our staff. Only trials that involved administering a drug for essential care, such as established anti-VEGF therapy for wet AMD or diabetic macular edema, continued uninterrupted.
We also continued administering investigational drugs to those undergoing clinical trials so as to not compromise the integrity of our studies. And that meant we had to be cautious from the very beginning of the virus spreading. It was only by creating a safe environment – providing proper sanitation, wearing masks, and allowing adequate space and time between patients – that we were able to continue delivering essential care to those who needed it most.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine